Quantum Cyber NV(QUCY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 24 at 7:43 PM ET (Korea 9/25 08:43)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 69.87% | Shs Outstand | 84.1M | Perf Week | -2.21% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 25.3M | Perf Month | -2.21% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -0.08 | Inst Own | 0.27% | Short Float | 7.36% | Perf Quarter | -8.28% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | -17.76% | Short Ratio | 0.99 | Perf Half Y | 166.37% |
| Sales | - | P/B | 1.63 | EPS next 5Y | 79.59% | ROA | - | Short Interest | 1.86M | Perf YTD | 18.75% |
| Book/sh | 0.81 | P/C | 8.36 | EPS past 3/5Y | 66.9% 8.38% | ROE | - | 52W High | -73.02% ($4.93) | Perf Year | -17.39% |
| Cash/sh | 0.16 | P/FCF | - | Sales past 3/5Y | 0.45% 1.7% | ROIC | - | 52W Low | 343.33% ($0.30) | Perf 3Y | -98.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.95% | Gross Margin | - | Volatility(W/M) | 4.83% 6.8% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.56 | EPS Q/Q | 97.59% | Profit Margin | - | RSI (14) | 46.32 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.56 | Sales Q/Q | -100% | SMA20 | -5.41% ($1.41) | Beta | 2.37 | Target Price | $9 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/04/14 | SMA50 | -0.34% ($1.33) | Rel Volume | 0.14 | Prev Close | $1.32 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - -58.95% | SMA200 | 9.92% ($1.21) | Avg Volume(3M) | 1.88M | Price | $1.33 |
| IPO | 2021/11/5 | Option/Short | No/Yes | Trades | 730 | Volume | 257,497 | Change | 0.76% |
Company
QUCY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This European biotech develops and sells molecular genetics-based early cancer diagnostic test kits. It is best known for ColoAlert, a stool-based colorectal cancer test, and in 2025, along with a company name change, its ticker changed from MYNZ to . It has recently been shifting its business focus toward early pancreatic cancer diagnostics.
Over the past 1 year, on the lower side
73% below its 1-year high.
QUCY makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +79.6% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by -98.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.3%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $112M.
QUCY $112M PER -
TMO $251B PER 36.5
DHR $157B PER 39.7
NTRA $59B PER -
FAQ
What kind of company is QUCY?
QUCY belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of QUCY?
The market cap of QUCY is approximately $112M, ranking 4,490 within its sector.
What is the 52-week high and low for QUCY?
QUCY has recorded a 52-week high of $4.93 and a low of $0.30.
